1. Home
  2. KXIN vs ARTL Comparison

KXIN vs ARTL Comparison

Compare KXIN & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

SELL

Current Price

$2.70

Market Cap

1.7M

ML Signal

SELL

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.21

Market Cap

1.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
ARTL
Founded
2015
2011
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.4M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
KXIN
ARTL
Price
$2.70
$2.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.1M
27.2K
Earning Date
12-17-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.52
52 Week High
$22.00
$179.19

Technical Indicators

Market Signals
Indicator
KXIN
ARTL
Relative Strength Index (RSI) 72.19 36.92
Support Level $0.42 $2.05
Resistance Level $2.81 $6.81
Average True Range (ATR) 0.21 0.24
MACD 0.10 0.07
Stochastic Oscillator 84.70 33.56

Price Performance

Historical Comparison
KXIN
ARTL

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: